摘要
<strong>Objective:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">To determine the prevalence of proteinuria in children living with HIV (CLHIV) and identify associated factors. </span><b><span style="font-family:Verdana;">Patients and methods: </span></b><span style="font-family:Verdana;">This was a cross-sectional, descriptive and analytical study carried out from April to August 2017 in the HIV care centres in Brazzaville and Pointe-Noire. The study included CLHIV with dipstick urinalysis test “Combur</span><sup><span style="font-family:Verdana;">10</span></sup><span style="font-family:Verdana;"> Test</span><sup><span style="font-family:Verdana;">®</span></sup><span style="font-family:Verdana;"> M”. </span><b><span style="font-family:Verdana;">Re</span><span style="font-family:Verdana;">sults: </span></b><span style="font-family:Verdana;">Thirty seven CLHIV on HAART presented a proteinuria, 21.8%. Children were male gender in 21 case</span></span><span style="font-family:Verdana;">s</span><span style="font-family:Verdana;"> (56.8%) and female gender in 16 cases (43.2%). Mean age was 10.9 ± 3.9 years. The children were infected with type 1 virus in 35 cases (94.6%), vertical transmission in all the cases (100%). Children were living with HIV for about 2 to 4 years of average n = 18 (48.6%)</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> and they were WHO clinical stage 2 in 18 cases (48.6%). 13 children (35%) had CD4 level < 200 cells/mm</span><sup><span style="font-family:Verdana;">3</span></sup><span style="font-family:Verdana;">. All CLHIV (100%) were on HAART thus 20 (37.7%) on the combination of zidovudine (AZT), lamivudine (3TC) and nevirapine (NVP). This combination AZT, 3TC, NVP was a protective factor regarding the occurrence of proteinuria (OR: 0.43;IC (95%). </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">Proteinuria </span><span style="font-family:Verdana;">is less observe</span></span><span style="font-family:Verdana;">d</span><span style="font-family:Verdana;"> in CLHIV on HAART. Systematic screening and early management of proteinuria during follow</span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">up of these children improve their survival</span><span style="font-family:Verdana;">.</span>
<strong>Objective:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">To determine the prevalence of proteinuria in children living with HIV (CLHIV) and identify associated factors. </span><b><span style="font-family:Verdana;">Patients and methods: </span></b><span style="font-family:Verdana;">This was a cross-sectional, descriptive and analytical study carried out from April to August 2017 in the HIV care centres in Brazzaville and Pointe-Noire. The study included CLHIV with dipstick urinalysis test “Combur</span><sup><span style="font-family:Verdana;">10</span></sup><span style="font-family:Verdana;"> Test</span><sup><span style="font-family:Verdana;">®</span></sup><span style="font-family:Verdana;"> M”. </span><b><span style="font-family:Verdana;">Re</span><span style="font-family:Verdana;">sults: </span></b><span style="font-family:Verdana;">Thirty seven CLHIV on HAART presented a proteinuria, 21.8%. Children were male gender in 21 case</span></span><span style="font-family:Verdana;">s</span><span style="font-family:Verdana;"> (56.8%) and female gender in 16 cases (43.2%). Mean age was 10.9 ± 3.9 years. The children were infected with type 1 virus in 35 cases (94.6%), vertical transmission in all the cases (100%). Children were living with HIV for about 2 to 4 years of average n = 18 (48.6%)</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> and they were WHO clinical stage 2 in 18 cases (48.6%). 13 children (35%) had CD4 level < 200 cells/mm</span><sup><span style="font-family:Verdana;">3</span></sup><span style="font-family:Verdana;">. All CLHIV (100%) were on HAART thus 20 (37.7%) on the combination of zidovudine (AZT), lamivudine (3TC) and nevirapine (NVP). This combination AZT, 3TC, NVP was a protective factor regarding the occurrence of proteinuria (OR: 0.43;IC (95%). </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">Proteinuria </span><span style="font-family:Verdana;">is less observe</span></span><span style="font-family:Verdana;">d</span><span style="font-family:Verdana;"> in CLHIV on HAART. Systematic screening and early management of proteinuria during follow</span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">up of these children improve their survival</span><span style="font-family:Verdana;">.</span>
作者
Lucie Charlotte Ollandzobo Ikobo
Roland Bienvenu Ossibi Ibara
Neli Yvette Ngakengni
Laren Babomi
Gaston Ekouya Bowassa
Linda Tchidjo Ngamo
Steve Vassili Missambou Mandilou
Sabrina Nadia Bouithy
Evrard Romaric Nika
Jean Robert Mabiala Babela
Lucie Charlotte Ollandzobo Ikobo;Roland Bienvenu Ossibi Ibara;Neli Yvette Ngakengni;Laren Babomi;Gaston Ekouya Bowassa;Linda Tchidjo Ngamo;Steve Vassili Missambou Mandilou;Sabrina Nadia Bouithy;Evrard Romaric Nika;Jean Robert Mabiala Babela(Faculty of Health Sciences, Marien Ngouabi University of Brazzaville, Brazzaville, Republic of Congo;Pediatric Services, Brazzaville University Hospital, Brazzaville, Republic of Congo;Infectious Diseases Service, Brazzaville University Hospital, Brazzaville, Republic of Congo;Department of Neonatology, Brazzaville University Hospital, Brazzaville, Republic of Congo;Department of Internal Medicine and Cardiology, Talangai Hospital, Brazzaville, Republic of Congo)
